Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Trans sodium crocetinate - CervoMed

Drug Profile

Trans sodium crocetinate - CervoMed

Alternative Names: Crocetin sodium salt; Sodium crocetinate; Trans sodium crocetinate; Transcrocetinate sodium; TSC; TSC-cpd

Latest Information Update: 17 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Office of Naval Research; University of Virginia
  • Developer CervoMed; Diffusion Pharmaceuticals; University of Virginia
  • Class Antineoplastics; Carotenoids; Dicarboxylic acids; Neuroprotectants; Radiation-sensitising agents; Small molecules; Vascular disorder therapies
  • Mechanism of Action Oxygen compound modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Brain metastases; Glioblastoma
  • New Molecular Entity Yes
  • Available For Licensing Yes - Glioblastoma

Highest Development Phases

  • Phase III Glioblastoma
  • Phase II Interstitial lung diseases; Stroke
  • Phase I/II COVID 2019 infections; SARS-CoV-2 acute respiratory disease
  • Phase I Brain metastases; Hypoxia; Pancreatic cancer
  • Discontinued Peripheral arterial disorders

Most Recent Events

  • 16 Aug 2023 EIP Pharma has merged with Diffusion Pharmaceuticals to form CervoMed
  • 31 Dec 2022 Diffusion Pharmaceuticals has multiple patents pending for Trans sodium crocetinate in USA and other multiple countries as of December 2022
  • 31 Dec 2022 Diffusion Pharmaceuticals has multiple patents protection for Trans sodium crocetinate in USA and other multiple countries as of December 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top